Skip to main content

Aralen Phosphate Side Effects

Generic name: chloroquine

Medically reviewed by Drugs.com. Last updated on Feb 15, 2023.

Note: This document contains side effect information about chloroquine. Some dosage forms listed on this page may not apply to the brand name Aralen Phosphate.

Applies to chloroquine: oral tablet.

Serious side effects of Aralen Phosphate

Along with its needed effects, chloroquine (the active ingredient contained in Aralen Phosphate) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking chloroquine:

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking chloroquine:

Symptoms of overdose

Other side effects of Aralen Phosphate

Some side effects of chloroquine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to chloroquine: compounding powder, injectable solution, oral tablet.

Ocular

Retinopathy and irreversible retinal damage have been reported during long-term, high-dose therapy.

Maculopathy and macular degeneration have been reported and may be irreversible.

Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance) and visual field defects (paracentral scotomas) have been reported in patients receiving long-term or high-dose 4-aminoquinoline therapy.[Ref]

Common (1% to 10%): Transient blurred vision

Rare (0.01% to 0.1%): Reversible corneal opacity, retinopathy, irreversible retinal damage

Frequency not reported: Retinal degeneration, macular defects of color vision, pigmentation, optic atrophy, scotomas, blindness, corneal opacity, pigmented deposits, vision blurred/difficulty focusing, accommodation disorder, diplopia, field defects, double vision, decreased visual acuity, color-vision defects, pigmentary retinopathy, corneal deposits, keratopathy, decreased corneal sensitivity, corneal edema

Postmarketing reports: Maculopathy, macular degeneration, visual disturbances (blurred vision, focusing/accommodation difficulty), nyctalopia, scotomatous vision with field defects of paracentral/pericentral ring types/typically temporal scotomas (e.g., difficulty in reading with words tending to disappear, seeing half an object, misty vision, fog before the eyes), reversible corneal opacities

4-aminoquinoline therapy:

-Postmarketing reports: Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance), visual field defects (paracentral scotomas)[Ref]

Dermatologic

Pruritus has been seen more commonly in Africans. The onset was generally 6 to 48 hours after the first dose and antihistamines did not always control the pruritus.

Pigmentation disorder (including bluish-black pigmentation of the nails and mucosa) has been reported with long-term use. Increased pigmentation of the skin and mucous membranes was generally of a bluish color was not always reversible on discontinuation.

Several cases of hypopigmentation of the skin have been reported. Most of the patients described were African or of African descent with dark skin who had been exposed to the sun. One was a Hispanic patient who developed vitiligo-like skin depigmentation after 1 month of therapy for cutaneous lupus erythematosus. The skin rapidly repigmented after this drug was discontinued.

At least 2 cases of exacerbation of psoriasis requiring hospitalization have been reported.[Ref]

Very common (10% or more): Pruritus

Common (1% to 10%): Skin eruptions, urticaria

Uncommon (0.1% to 1%): Alopecia, pigmentation disorder (including bluish-black pigmentation of the nails and mucosa)

Rare (0.01% to 0.1%): Exacerbation/precipitation of psoriasis, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome

Very rare (less than 0.01%): Exfoliative dermatitis, similar desquamation-type events

Frequency not reported: Macular/urticarial/purpuric skin eruptions, lichenoid keratosis, acute generalized exanthematous pustulosis, depigmentation, rashes

Postmarketing reports: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, pleomorphic skin eruptions, lichen planus-like eruptions, hair loss, skin/mucosal pigmentary changes, pruritus, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, bleaching of hair pigment, photosensitivity reaction[Ref]

Gastrointestinal

Very common (10% or more): Gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea)

Frequency not reported: Gastrointestinal disorder, abdominal pain

Postmarketing reports: Nausea, vomiting, diarrhea, abdominal cramps[Ref]

Nervous system

Very common (10% or more): Headache

Uncommon (0.1% to 1%): Neuropathy, ototoxicity (e.g., tinnitus, hypoacusis, deafness neurosensory/nerve deafness)

Rare (0.01% to 0.1%): Convulsions, polyneuropathy

Frequency not reported: Visual field defects, neuromyopathy, convulsive seizures, polyneuritis, dizziness, nonconvulsive status epilepticus/seizures, development of extrapyramidal rigidity

Postmarketing reports: Convulsions, mild headache (transient), polyneuropathy, acute extrapyramidal disorders (e.g., dystonia, dyskinesia, tongue protrusion, torticollis), sensorimotor disorders, depression of tendon reflexes, abnormal nerve conduction, nerve type deafness, tinnitus, reduced hearing (in patients with preexisting auditory damage)[Ref]

Psychiatric

Mania has been reported in a patient taking this drug for malarial prophylaxis. These symptoms resolved after discontinuation and recurred with rechallenge.[Ref]

Very common (10% or more): Insomnia

Common (1% to 10%): Depression

Rare (0.01% to 0.1%): Hallucinations, psychiatric disorders (e.g., anxiety, agitation, confusion, hallucinations, delirium)

Frequency not reported: Mania, other psychiatric and neurologic disturbances, paranoia

Postmarketing reports: Neuropsychiatric changes, psychotic disorder/psychosis, delirium, anxiety, agitation, insomnia, confusion, hallucinations, personality changes, depression, suicidal behavior[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity/allergic reaction (including urticaria, angioedema, vasculitis), anaphylactic reactions

Frequency not reported: Anaphylactoid reaction

Postmarketing reports: Anaphylactic reaction (including angioedema)

Cardiovascular

Uncommon (0.1% to 1%): Cardiomyopathy

Rare (0.01% to 0.1%): Cardiac arrhythmias (including QT prolongation, torsade de pointes, ventricular tachycardia, ventricular fibrillation)

Frequency not reported: Atrioventricular block, cardiac hypertrophy, restrictive cardiomyopathy, congestive heart failure, complete heart block

Postmarketing reports: Hypotension, ECG changes (particularly inversion/depression of T-wave with widening of QRS complex), cardiomyopathy (sometimes resulting in cardiac failure; some with fatal outcome), cardiac arrhythmias, conduction disorders (e.g., bundle branch block/atrioventricular block), QT interval prolongation, torsade de pointes, ventricular tachycardia, ventricular fibrillation[Ref]

Cardiomyopathy has been reported during long-term therapy at high doses.

Cardiac arrhythmias (including QT prolongation, torsade de pointes, ventricular tachycardia, and ventricular fibrillation) have been reported with therapeutic doses as well as with overdose; the risk was greater when high doses were administered. Fatal cases have been reported.

ECG changes have been reported at high doses. ECG changes observed included prolongation of the QRS interval and, rarely, complete heart block. Biopsies of cardiac tissue characteristically showed no inflammatory infiltrates, severe vacuolation, and myocytes containing myeloid bodies and lysosomes.

Conduction disorders (e.g., bundle branch block/atrioventricular block) have been reported with therapeutic doses as well as with overdose.[Ref]

Musculoskeletal

Uncommon (0.1% to 1%): Myopathy

Frequency not reported: Myasthenia-like syndromes

Postmarketing reports: Skeletal muscle myopathy/neuromyopathy (leading to progressive weakness, atrophy of proximal muscle groups)[Ref]

Hematologic

Rare (0.01% to 0.1%): Bone marrow failure/depression (including aplastic anemia, agranulocytosis, pancytopenia, thrombocytopenia, neutropenia)

Postmarketing reports: Pancytopenia, aplastic anemia, reversible agranulocytosis, thrombocytopenia, neutropenia, hemolytic anemia (in glucose-6-phosphate dehydrogenase deficient patients)[Ref]

Hepatic

Rare (0.01% to 0.1%): Changes in liver function (including hepatitis, abnormal liver function tests)

Frequency not reported: Hepatotoxicity (in a patient with porphyria cutanea tarda)

Postmarketing reports: Hepatitis, elevated liver enzymes[Ref]

Metabolic

Frequency not reported: Hypokalemia (associated with acute ingestion)

Postmarketing reports: Anorexia, hypoglycemia[Ref]

The usefulness of hypokalemia as an indicator in the evaluation of chloroquine toxicity was studied in a retrospective series of 191 acute chloroquine poisonings. Results indicated that the risk of severe poisoning and death were proportional to the degree of hypokalemia.[Ref]

Respiratory

Frequency not reported: Diffuse parenchymal lung disease[Ref]

Frequently asked questions

References

1. Sassani JW, Brucker AJ, Cobbs W, Campbell C. Progressive chloroquine retinopathy. Ann Ophthalmol. 1983;15:19-22.

2. Ehrenfeld M, Nesher R, Merin S. Delayed-onset chloroquine retinopathy. Br J Ophthalmol. 1986;70:281-3.

3. Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al. Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics. Clin Pharmacol Ther. 1979;25:345-50.

4. Craig GL, Buchanan WW. Antirheumatic drugs: clinical pharmacology and therapeutic use. Drugs. 1980;20:453-84.

5. Goldstein JH. Effects of drugs on cornea, conjunctiva, and lids. Int Ophthalmol Clin. 1971;11:13-34.

6. Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchana. Ocular toxicity of chloroquine among Thai patients. Int J Dermatol. 1999;38:934-7.

7. Thorogood N, Atwal S, Mills W, et al. The risk of antimalarials in patients with renal failure. Postgrad Med J. 2007;83:e8.

8. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med. 2008;359:603-12.

9. Tonnesmann E, Stroehmann I, Kandolf R, et al. Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or a rare diagnosis? J Rheumatol. 2012;39:1099-103.

10. Olsen TG. Chloroquine and psoriasis. Ann Intern Med. 1981;94:546-7.

11. Spencer HC, Poulter NR, Lury JD, Poulter CJ. Chloroquine-associated pruritus in a European. Br Med J. 1982;285:1703-4.

12. Van Weelden HV, Bolling HH, De La Faille HB, et al. Photosensitivity caused by chloroquine. Arch Dermatol. 1982;118:290.

13. Levy H. Chloroquine-induced pigmentation. S Afr Med J. 1982;62:735-7.

14. Mallett R. Risks and benefits of prophylactic antimalarial drugs. Br Med J. 1989;299:1400.

15. Okor RS. Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy. J Clin Pharm Ther. 1991;16:463-5.

16. Ajayi AA, Akinleye AO, Udoh SJ, et al. The effects of prednisolone and niacin on chloroquine-induced pruritis in malaria. Eur J Clin Pharmacol. 1991;41:383-5.

17. Olatunde IA. Chloroquine concentrations in the skin of rabbits and man. Br J Clin Pharmacol. 1971;43:335-40.

18. Vestey JP, Savin JA. Psoriasis worsened by antimalarial prophylaxis. J Infect. 1992;24:211-2.

19. Boffa MJ, Chalmers RJG. Toxic epidermal necrolysis due to chloroquine phosphate. Br J Dermatol. 1994;131:444-5.

20. Selvaag E. Chloroquine-induced vitiligo - a case report and review of the literature. Acta Derm Venereol. 1996;76:166-7.

21. Janier M, Froidevaux D, LonsDanic D, Daniel F. Acute generalized exanthematous pustulosis due to the combination of chloroquine and proguanil. Dermatology. 1998;196:271.

22. Wilairatana P, Looareesuwan S, Riganti M, TejaIsavadharm P, Keeratithakul D, Eickmeyer S, Walsh DS. Pustular eruption in a malaria patient treated with chloroquine. Int J Dermatol. 1998;37:713-4.

23. Ezeamuzie IC, Igbigbi PS, Ambakederemo AW, Abila B, Nwaejike IN. Halofantrine-induced pruritus amongst subjects who itch to chloroquine. J Trop Med Hyg. 1991;94:184-8.

24. Martin-Garcia RF, Camacho Ndel R, Sanchez JL. Chloroquine-induced, vitiligo-like depigmentation. J Am Acad Dermatol. 2003;48:981-3.

25. Schlagenhauf P, Tschopp A, Johnson R, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003;327:1078.

26. Rustogi A, Munshi A, Jalali R. Unexpected skin reaction induced by radiotherapy after chloroquine use. Lancet Oncol. 2006;7:608-9.

27. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg. 2000;94:419-24.

28. Donovan JC, Price VH. Images in clinical medicine. Chloroquine-induced hair hypopigmentation. N Engl J Med. 2010;363:372.

29. Bhasin DK, Chhina RS, Sachdeva JR. Endoscopic assessment of chloroquine phosphate-induced damage to esophageal, gastric, and duodenal mucosa. Am J Gastroenterol. 1991;86:434-7.

30. Liu AC. Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda. West J Med. 1995;162:548-51.

31. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-23.

32. Product Information. Aralen (chloroquine). Sanofi Winthrop Pharmaceuticals. 2002;PROD.

33. Mulhauser P, Allemann Y. Chloroquine and nonconvulsive status epilepticus. Ann Intern Med. 1995;123:76-7.

34. Benbadis SR, Vanness PC. Chloroquine and nonconvulsive status epilepticus. Ann Intern Med. 1996;124:614.

35. Singh RP, Sinha AK. Neuropsychiatric toxicity of chlorquine. J Indian Med Assoc. 1981;77:133-4.

36. Mohan D, Mohandas E, Rajat R. Chloroquine psychosis: a chemical psychosis? J Natl Med Assoc. 1981;73:1073-6.

37. Lovestone S. Chloroquine-induced mania. Br J Psychiatry. 1991;159:164-5.

38. Akhtar S, Mukherjee S. Chloroquine induced mania. Int J Psychiatry Med. 1993;23:349-56.

39. Telgt DS, van der Ven AJ, Schimmer B, Droogleever-Fortuyn HA, Sauerwein RW. Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. Ann Pharmacother. 2005;39:551-4.

40. Cooper RG. Chloroquine should be used with care in mental health disorders. Indian J Physiol Pharmacol. 2008;52:97-8.

41. Looareesuwan S, White NJ, Chanthavanich P, et al. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol. 1986;22:31-6.

42. McAllister HA Jr, Ferrans VJ, Hall RJ et al. Cholorquine-induced cardiomyopathy. Arch Pathol Lab Med. 1987;111:953-6.

43. Ratliff NB, Este ML, Myles JL, et al. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med. 1987;316:191-3.

44. Iglesias Cubero G, Rodriguez Reguero JJ, Rojo Ortega JM. Restrictive cardiomyopathy caused by chloroquine. Br Heart J. 1993;69:451-2.

45. Veinot JP, Mai KT, Zarychanski R. Chloroquine related cardiac toxicity. J Rheumatol. 1998;25:1221-5.

46. Baguet JP, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart. 1999;81:221-3.

47. ReussBorst M, Berner B, Wulf G, Muller GA. Complete heart block as a rare complication of treatment with chloroquine. J Rheumatol. 1999;26:1394-5.

48. Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Cardiomyopathy Related to Antimalarial Therapy with Illustrative Case Report. Cardiology. 2006;107:73-80.

49. Parodi A, Regesta G, Rebora A. Chloroquine-induced neuromyopathy. Dermatologica. 1985;171:203-5.

50. Hearn J, Tiliakos NA. Myasthenia gravis caused by pencillamine and chloroquine therapy for rheumatoid arthritis. South Med J. 1986;79:1185-6.

51. Estes ML, Wing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Am J Med. 1987;82:447-55.

52. Schirlanzoni A, Mantegazza R, Mora M, et al. Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve. 1988;11:114-9.

53. Robberecht W, Bednarik J, Bourgeois P, et al. Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. Arch Neurol. 1989;46:464-8.

54. Avinazubieta JA, Johnson ES, Suarezalmazor ME, Russell AS. Incidence of myopathy in patients treated with antimalarials. a report of three cases and a review of the literature. Br J Rheumatol. 1995;34:166-70.

55. Nucci A, Queiroz LS, Samara AM. Chloroquine neuromyopathy. Clin Neuropathol. 1996;15:256-8.

56. Wasay M, Wolfe GI, Herrold JM, Burns DK, Barohn RJ. Chloroquine myopathy and neuropathy with elevated CSF protein. Neurology. 1998;51:1226-7.

57. Polano MK, Cats A, van Olden GAJ. Agranulocytosis following treatment with hydroxychloroquine sulphate. Lancet. 1965;1:1275.

58. Winkelman RK, Merwin CF, Brunsting LA. Antimalarial therapy of lupus erythematosus. Ann Intern Med. 1961;55:772-6.

59. Angel G, Berthelot PG, Rogier C. Hypokalaemia related to acute chloroquine poisoning. Lancet. 1995;346:1625.

60. Buchanan N. Hypokalaemia and acute chloroquine ingestion. Lancet. 1996;347:404.

61. Clemessy JL, Borron SW, Baud FJ. Hypokalaemia and acute chloroquine ingestion - reply. Lancet. 1996;347:404-5.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.